# US 2022/0088133 A1 · Nanoliposome Compositions And Methods Of Treating Stroke

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0088133 A1
- Document ID: US20220088133A1
- Status: Published application
- Kind: A1
- Application number: 17/472,324
- Filed: 2021-09-10
- Published: 2022-03-24
- Earliest claimed: 2020-09-11
- Assignees: The United States Government as represented by the Department of Veterans Affairs; Midwestern University
- Applicants: United States Government As Represented By The Department of Veterans Affairs; Midwestern University
- Inventors: Raymond Q. Migrino; Volkmar Weissig
- Web page: https://patentgrep.com/patent/US20220088133A1

## CPC

- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 38/1761: {Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2}
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 9/1272: comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents {A61K47/543})
- A61K 31/575: substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A61K 31/685: one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
- A61K 31/7032: attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 38/1709: {from mammals}
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61K 47/28: Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are compositions comprising nanoliposomes useful for the treatment and prevention of stroke.

## Claims

### Claim 1

A method of treating stroke, the method comprising administering to a subject a therapeutically effective amount of a composition comprising a nanoliposome, wherein the nanoliposome comprises a phospholipid, cholesterol, and a glycosphingolipid moiety.

### Claim 2

A method of reducing or preventing endothelial cell or vascular hypoxic/ischemic injury in a subject, the method comprising administering to the subject a therapeutically effective amount of a composition comprising a nanoliposome, wherein the nanoliposome comprises a phospholipid, cholesterol, and a glycosphingolipid moiety.

### Claim 3

A method of reducing or preventing medin-mediated injury in a subject, the method comprising administering to the subject a therapeutically effective amount of a composition comprising a nanoliposome, wherein the nanoliposome comprises a phospholipid, cholesterol, and a glycosphingolipid moiety.

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The method of claim 1, wherein the subject has ischemic cerebrovascular disease.

### Claim 6 (depends on 1)

The method of claim 1, wherein the subject has an ischemic injury caused by atherosclerotic cerebrovascular disease.

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The method of claim 1, wherein the subject does not have increased or elevated levels of medin.

### Claim 9 (depends on 1)

The method of claim 1, wherein the phospholipid is phosphatidylcholine or phosphatidic acid.

### Claim 10 (depends on 1)

The method of claim 1 The method of any of the preceding claims, wherein the glycosphingolipid moiety is a cerebroside, ganglioside or a globoside.

### Claim 11 (depends on 10)

The method of claim 10, wherein the glycosphingolipid moiety is a ganglioside.

### Claim 12 (depends on 11)

The method of claim 11, wherein the ganglioside is GM1, GM2, GM3, GD1a, GD1b, GD2, GD3, GT1b, GT3 or GQ1.

### Claim 13 (depends on 12)

The method of claim 12, wherein the ganglioside is monosialoganglioside (GM1).

### Claim 14 (depends on 1)

The method of claim 1, wherein the phospholipid, cholesterol, and glycosphingolipid moiety are present in a molar ratio of 70:25:5, respectively.

### Claim 15 (depends on 13)

The method of claim 13, wherein the composition comprises phosphatidylcholine, cholesterol, and monosialoganglioside (GM1) in a molar ratio of 70:25:5, respectively.

### Claim 16 (depends on 1)

The method of claim 1, wherein the administration of the composition increases one or more antioxidant enzymes.

### Claim 17 (depends on 1)

The method of claim 1, wherein the administration of the composition increases one more or transcription factors.

### Claim 18 (depends on 1)

The method of claim 1, wherein the administration of the composition increases nitric oxide bioavailability.

### Claim 19 (depends on 1)

The method of claim 1, wherein the administration of the composition reduces one or more proinflammatory cytokines or one or more prothrombotic cytokines.

### Claim 20 (depends on 19)

The method of claim 19, wherein the one or more proinflammatory cytokines are IL-1β, IL-8, TNF-α or IL-6.

### Claim 21 (depends on 19)

The method of claim 19, wherein the one or more prothrombotic cytokines are ICAM-1, VCAM-1, MCP, caspase-1 or PAI-1.

### Claim 22 (depends on 16)

The method of claim 16, wherein the one or more antioxidant enzymes are heme-oxygenase 1 (HO-1), NADPH quinone dehydrogenase (NQO1), superoxide dismutase 1 (SOD1), catalase, glutathione peroxidase, peroxiredoxin I and II, thioredoxin, myeloperoxidase, thioredoxin reductase, or a combination thereof.

### Claim 23 (depends on 17)

The method of claim 17, wherein the one or more of the transcription factors is nuclear factor erythroid 2-related factor 2 (Nrf2).

### Claim 24

(canceled)

### Claim 25 (depends on 1)

The method of claim 1, wherein the composition further comprises a therapeutic cargo.

### Claim 26 (depends on 25)

The method of claim 25, wherein the therapeutic cargo is clusterin, apolipoprotein J, apolipoprotein E, an antibody fragment, an aptamer, a small interfering RNA (siRNA), or a short hairpin RNA (shRNA).

### Claim 27 (depends on 26)

The method of claim 26, wherein the clusterin is secretory clusterin (sCLU).

### Claim 28

(canceled)

### Claim 29 (depends on 1)

The method of claim 1, wherein the subject is identified in need of treatment before the administration step.

### Claim 30 (depends on 1)

The method of claim 1, wherein the subject is identified as not having an increased level of medin protein compared to a control subject.

### Claim 31

(canceled)
